BioCryst Pharmaceuticals Inc (BCRX)
7.05
-0.30
(-4.02%)
USD |
NASDAQ |
Nov 05, 16:00
7.06
+0.01
(+0.14%)
After-Hours: 19:17
BioCryst Pharmaceuticals Cash from Financing (Quarterly): -1.966M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -1.966M |
| March 31, 2024 | -1.048M |
| December 31, 2023 | -3.173M |
| September 30, 2023 | 1.225M |
| June 30, 2023 | 29.36M |
| March 31, 2023 | 5.077M |
| December 31, 2022 | 4.199M |
| September 30, 2022 | 76.32M |
| June 30, 2022 | 0.147M |
| March 31, 2022 | 7.356M |
| December 31, 2021 | 347.42M |
| September 30, 2021 | 4.776M |
| June 30, 2021 | 4.574M |
| March 31, 2021 | 2.90M |
| December 31, 2020 | 196.76M |
| September 30, 2020 | -4.634M |
| June 30, 2020 | 108.20M |
| March 31, 2020 | 0.266M |
| December 31, 2019 | 78.46M |
| September 30, 2019 | 0.184M |
| June 30, 2019 | 0.414M |
| March 31, 2019 | 20.04M |
| December 31, 2018 | 1.337M |
| September 30, 2018 | 63.92M |
| June 30, 2018 | -1.275M |
| Date | Value |
|---|---|
| March 31, 2018 | -1.476M |
| December 31, 2017 | 0.573M |
| September 30, 2017 | 86.31M |
| June 30, 2017 | 0.118M |
| March 31, 2017 | 48.70M |
| December 31, 2016 | 2.332M |
| September 30, 2016 | 22.34M |
| June 30, 2016 | -1.501M |
| March 31, 2016 | 0.138M |
| December 31, 2015 | 0.087M |
| September 30, 2015 | 0.647M |
| June 30, 2015 | 3.244M |
| March 31, 2015 | 1.501M |
| December 31, 2014 | 0.361M |
| September 30, 2014 | 3.373M |
| June 30, 2014 | 105.77M |
| March 31, 2014 | 2.402M |
| December 31, 2013 | 1.891M |
| September 30, 2013 | 20.01M |
| June 30, 2013 | 5.325M |
| March 31, 2013 | 3.04M |
| December 31, 2012 | 0.316M |
| September 30, 2012 | 2.137M |
| June 30, 2012 | 2.582M |
| March 31, 2012 | 11.92M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-4.634M
Minimum
Sep 2020
347.42M
Maximum
Dec 2021
45.06M
Average
4.574M
Median
Jun 2021
Cash from Financing (Quarterly) Benchmarks
| Novavax Inc | 258.22M |
| AIM ImmunoTech Inc | 2.441M |
| Perspective Therapeutics Inc | 122.08M |
| Protalix BioTherapeutics Inc | 0.00 |
| Armata Pharmaceuticals Inc | 0.088M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.368M |
| Cash from Investing (Quarterly) | -2.449M |
| Free Cash Flow | -85.80M |
| Free Cash Flow Per Share (Quarterly) | -0.0074 |
| Free Cash Flow to Equity (Quarterly) | 3.032M |
| Free Cash Flow to Firm (Quarterly) | 19.95M |
| Free Cash Flow Yield | -6.06% |